MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio
January 10, 2022 02:00 ET
|
MeMed
MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV® test recently cleared for use by US FDA to aid in distinguishing between bacterial and viral...
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children
December 01, 2021 07:00 ET
|
MeMed
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children The study demonstrated the test’s high performance in...
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children
December 01, 2021 02:00 ET
|
MeMed
Clinical data published in Clinical Microbiology and Infection support use of MeMed’s test in reducing antibiotic overuse in children The study demonstrated the test’s high performance in...
FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform
September 20, 2021 02:00 ET
|
MeMed
FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform MeMed BV is a first-of-its kind test...
FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform
September 20, 2021 02:00 ET
|
MeMed
FDA Clears First Technology to Distinguish between Bacterial and Viral Infections Using the Body’s Immune Response – The MeMed BV® Test and MeMed Key® Platform MeMed BV is a first-of-its kind test...
MeMed Named a Finalist for AACC’s Disruptive Technology Award for MeMed COVID-19 Severity™ Test
August 05, 2021 07:00 ET
|
MeMed
MeMed Named a Finalist for AACC’s Disruptive Technology Award for MeMed COVID-19 Severity™ Test MeMed COVID-19 Severity reads the immune-system in real time to accurately determine whether...
MeMed的COVID-19 Severity测试方法获得CE标志，用于预测新冠肺炎患者的严重预后
July 27, 2021 02:00 ET
|
MeMed
MeMed的COVID-19 Severity测试方法获得CE标志，用于预测新冠肺炎患者的严重预后MeMed COVID-19 Severity可实时读取免疫系统信息以准确确定感染新冠病毒的患者是否可能出现严重结局以色列海法，2021年7月27日–宿主响应技术领域领先企业MeMed今天宣布，其新推出的疾病管理解决方案MeMed COVID-19 Severity™在欧洲获得了CE标志。MeMed...
Il test di gravità del COVID-19 di MeMed ottiene il marchio CE per la previsione di esiti gravi nei pazienti affetti da COVID-19
July 27, 2021 02:00 ET
|
MeMed
Il test di gravità del COVID-19 di MeMed ottiene il marchio CE per la previsione di esiti gravi nei pazienti affetti da COVID-19Il test di gravità del COVID-19 di MeMed analizza il sistema immunitario...
Le test MeMed COVID-19 Severity reçoit le marquage CE pour la prévision des complications sévères chez les patients atteints de COVID-19
July 27, 2021 02:00 ET
|
MeMed
Le test MeMed COVID-19 Severity reçoit le marquage CE pour la prévision des complications sévères chez les patients atteints de COVID-19MeMed COVID-19 Severity évalue le système immunitaire en temps...
MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 Patients
July 27, 2021 02:00 ET
|
MeMed
MeMed’s COVID-19 Severity Test Receives CE Mark for Predicting Severe Outcomes in COVID-19 PatientsMeMed COVID-19 Severity reads the immune-system in real time to accurately determine whether...